Pyrocardan® implant interposition in the trapeziometacarpal joint: outcomes at a minimum 10 years’ follow-up - 28/12/24
, Ludovic Ardouin, Flore-Anne Lecoq, Clara Sos, Philippe BellemèreAbstract |
Objective |
We present long-term results for the Pyrocardan®, a pyrocarbon trapeziometacarpal interposition implant used for the treatment of osteoarthritis of the thumb.
Methods |
Between March 2009 and May 2013, 199 arthroplasties were performed in a single hand center, in 184 patients by 6 hand surgeons.
107 implants were followed up for a mean 137 months (range, 120 to 168 months). 82 patients (89 implants) were lost to follow-up.
Results |
Median age was 57 years, with 15 patients (14.2%) aged ≤50 years.
At last follow-up, functional scores were significantly improved compared to preoperative data: pain rating, 0.4/10 versus 7.2/10; Patient-Rated Wrist/Hand Evaluation, 4/100 versus 61/100; Quick Disabilities of the Arm, Shoulder and Hand, 9/100 versus 54/100.
Range of motion and strength were comparable to the contralateral side. Radiographic analysis showed that 82% of implants were correctly positioned. No implant dislocation was observed. There were 6 re-operations, 5 of which in the short term.
Overall implant survival was 94.3%, with 44.7% loss to follow-up.
Conclusion |
Pyrocardan® interposition arthroplasty is a valid alternative for the treatment of osteoarthritis of the thumb.
Level of evidence |
IV
Le texte complet de cet article est disponible en PDF.Keywords : trapeziometacarpal joint, osteoarthritis, arthroplasty, pyrocarbon interposition, Pyrocardan implant.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?